Pulse Biosciences (NASDAQ:PLSE) Upgraded by StockNews.com to “Sell” Rating

Pulse Biosciences (NASDAQ:PLSE) was upgraded by stock analysts at StockNews.com to a “sell” rating in a research note issued to investors on Thursday.

Pulse Biosciences Trading Up 10.3 %

Shares of NASDAQ PLSE opened at $19.63 on Thursday. The company has a 50-day simple moving average of $18.06 and a 200-day simple moving average of $16.95. Pulse Biosciences has a 12 month low of $6.59 and a 12 month high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period in the previous year, the firm earned ($0.19) EPS.

Insider Activity at Pulse Biosciences

In other Pulse Biosciences news, CEO Burke Thomas Barrett sold 50,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total transaction of $871,000.00. Following the transaction, the chief executive officer now owns 63,172 shares of the company’s stock, valued at $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Robert W. Duggan purchased 55,256 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was bought at an average price of $17.18 per share, for a total transaction of $949,298.08. Following the acquisition, the director now owns 42,328,717 shares in the company, valued at $727,207,358.06. The trade was a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 71.50% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp raised its holdings in shares of Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after purchasing an additional 69,696 shares during the period. Geode Capital Management LLC increased its position in Pulse Biosciences by 7.8% during the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after purchasing an additional 33,200 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Pulse Biosciences by 193.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock valued at $2,598,000 after buying an additional 97,565 shares during the period. Bank of New York Mellon Corp lifted its position in Pulse Biosciences by 23.4% during the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock valued at $570,000 after buying an additional 9,639 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Pulse Biosciences during the third quarter worth approximately $588,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.